CN106350490A - 利用无血清培养基从成纤维细胞中获得神经细胞的方法 - Google Patents
利用无血清培养基从成纤维细胞中获得神经细胞的方法 Download PDFInfo
- Publication number
- CN106350490A CN106350490A CN201610952074.4A CN201610952074A CN106350490A CN 106350490 A CN106350490 A CN 106350490A CN 201610952074 A CN201610952074 A CN 201610952074A CN 106350490 A CN106350490 A CN 106350490A
- Authority
- CN
- China
- Prior art keywords
- serum
- cell
- concentration
- free medium
- neurocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000012679 serum free medium Substances 0.000 title claims abstract description 37
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 28
- 210000002569 neuron Anatomy 0.000 title abstract description 13
- 239000001963 growth medium Substances 0.000 claims abstract description 27
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 18
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 11
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 9
- 230000000996 additive effect Effects 0.000 claims abstract description 9
- 230000014509 gene expression Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 69
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 64
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 46
- 102000004877 Insulin Human genes 0.000 claims description 32
- 108090001061 Insulin Proteins 0.000 claims description 32
- 229940125396 insulin Drugs 0.000 claims description 32
- 229960001471 sodium selenite Drugs 0.000 claims description 24
- 235000015921 sodium selenite Nutrition 0.000 claims description 24
- 239000011781 sodium selenite Substances 0.000 claims description 24
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 23
- 239000007640 basal medium Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 102000013275 Somatomedins Human genes 0.000 claims description 10
- 230000006698 induction Effects 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000010261 cell growth Effects 0.000 claims description 7
- 210000005036 nerve Anatomy 0.000 claims description 6
- 238000010166 immunofluorescence Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229930182816 L-glutamine Natural products 0.000 claims description 2
- 101100075995 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fma2 gene Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 14
- 108091023040 Transcription factor Proteins 0.000 abstract description 3
- 102000040945 Transcription factor Human genes 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- -1 small molecule compound Chemical class 0.000 abstract description 2
- 239000003102 growth factor Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 210000001161 mammalian embryo Anatomy 0.000 description 18
- 210000001178 neural stem cell Anatomy 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000005138 cryopreservation Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000000630 fibrocyte Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 101150051019 Klrg1 gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 101150084866 MAFA gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 102100038553 Neurogenin-3 Human genes 0.000 description 1
- 101150111723 PDX1 gene Proteins 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000002718 aborted fetus Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 210000002266 hair cells auditory Anatomy 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000004336 spermatogonium Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
Abstract
Description
转铁蛋白 | 胰岛素 | bFGF | 2-巯基乙醇 | 亚硒酸钠 | EGF | B27 | |
A | 5.5ng/ml | 10ng/ml | 20ng/ml | 50μg/ml | 0 | 0 | 0 |
B | 5.5ng/ml | 10ng/ml | 20ng/ml | 0 | 67μg/ml | 0 | 0 |
C | 5.5ng/ml | 10ng/ml | 20ng/ml | 50μg/ml | 67μg/ml | 20ng/ml | 0 |
D | 5.5ng/ml | 10ng/ml | 20ng/ml | 50μg/ml | 67μg/ml | 0 | 2% |
E | 5.5ng/ml | 10ng/ml | 20ng/ml | 0 | 0 | 0 | 0 |
F | 0 | 10ng/ml | 20ng/ml | 50μg/ml | 0 | 0 | 0 |
G | 0 | 10ng/ml | 20ng/ml | 0 | 67μg/ml | 0 | 0 |
H | 5.5ng/ml | 10ng/ml | 0 | 50μg/ml | 0 | 0 | 0 |
I | 5.5ng/ml | 10ng/ml | 0 | 0 | 67μg/ml | 0 | 0 |
J | 5.5ng/ml | 0 | 20ng/ml | 50μg/ml | 0 | 0 | 0 |
K | 5.5ng/ml | 0 | 20ng/ml | 0 | 67μg/ml | 0 | 0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610952074.4A CN106350490B (zh) | 2016-11-02 | 2016-11-02 | 利用无血清培养基从成纤维细胞中获得神经细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610952074.4A CN106350490B (zh) | 2016-11-02 | 2016-11-02 | 利用无血清培养基从成纤维细胞中获得神经细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106350490A true CN106350490A (zh) | 2017-01-25 |
CN106350490B CN106350490B (zh) | 2019-10-11 |
Family
ID=57865102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610952074.4A Active CN106350490B (zh) | 2016-11-02 | 2016-11-02 | 利用无血清培养基从成纤维细胞中获得神经细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106350490B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107151656A (zh) * | 2017-05-10 | 2017-09-12 | 中国科学院广州生物医药与健康研究院 | 一种提高体细胞向神经细胞转分化效率的方法 |
CN116396928A (zh) * | 2023-05-12 | 2023-07-07 | 细新(上海)医疗科技有限公司 | 一种原代成纤维细胞的培养体系、培养方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080152630A1 (en) * | 2006-12-07 | 2008-06-26 | Irene Ginis | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
CN102533653A (zh) * | 2011-12-15 | 2012-07-04 | 中国人民解放军第二军医大学 | MSCs、ASCs诱导的5-HT神经细胞及其微囊化制备方法与应用 |
CN105087481A (zh) * | 2015-08-21 | 2015-11-25 | 深圳爱生再生医学科技有限公司 | 无血清培养基及干细胞的培养方法 |
-
2016
- 2016-11-02 CN CN201610952074.4A patent/CN106350490B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080152630A1 (en) * | 2006-12-07 | 2008-06-26 | Irene Ginis | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
CN102533653A (zh) * | 2011-12-15 | 2012-07-04 | 中国人民解放军第二军医大学 | MSCs、ASCs诱导的5-HT神经细胞及其微囊化制备方法与应用 |
CN105087481A (zh) * | 2015-08-21 | 2015-11-25 | 深圳爱生再生医学科技有限公司 | 无血清培养基及干细胞的培养方法 |
Non-Patent Citations (3)
Title |
---|
SU MIN LIM ET AL.: "Patient fibroblasts-derived induced neurons demonstrate autonomous neuronal defects in adult-onset Krabbe disease", 《ONCOTARGET》 * |
XIAODONG ZHANG ET AL.: "Adult human olfactory neural progenitors cultured in defined medium.", 《EXPERIMENTAL NEUROLOGY》 * |
杨丽红: "VEGF转染对MSCs向神经细胞诱导分化的影响", 《中华神经外科疾病研究杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107151656A (zh) * | 2017-05-10 | 2017-09-12 | 中国科学院广州生物医药与健康研究院 | 一种提高体细胞向神经细胞转分化效率的方法 |
CN116396928A (zh) * | 2023-05-12 | 2023-07-07 | 细新(上海)医疗科技有限公司 | 一种原代成纤维细胞的培养体系、培养方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106350490B (zh) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brewer | Isolation and culture of adult rat hippocampal neurons | |
CN103396993B (zh) | 衍生自灵长类胚胎干细胞的用于脊髓损伤的再髓鞘化和治疗的少突胶质细胞 | |
CN110484506B (zh) | 胶质母细胞瘤类器官模型的构建方法和应用 | |
CN105861428B (zh) | 一种诱导成纤维细胞转分化为心肌细胞的诱导培养基及其应用 | |
CN102191221A (zh) | 一种能无限自我更新的神经干细胞、其制备方法及其用途 | |
CN102228718A (zh) | 一种组织工程化神经组织及其构建方法 | |
Yang et al. | A simple and efficient method for deriving neurospheres from bone marrow stromal cells | |
CN104774808B (zh) | 将脐带间充质干细胞诱导分化成γ-氨基丁酸能神经元的方法 | |
CN109266610B (zh) | 一种促进间充质干细胞分化为神经元的方法 | |
CN105420193B (zh) | 分化培养基及其在制备神经干细胞中的用途 | |
RU2433172C2 (ru) | Способ получения гомогенной популяции стволовых клеток и ее применение | |
CN105754935B (zh) | 一种诱导成纤维细胞转分化为脂肪细胞的诱导培养基及其应用 | |
An et al. | Effect of rat Schwann cell secretion on proliferation and differentiation of human neural stem cells | |
CN106282113A (zh) | 一种利用无血清培养基通过转分化获得神经细胞的方法 | |
CN106244548A (zh) | 木犀草素在诱导间充质干细胞向神经细胞定向分化中的用途 | |
CN106350490A (zh) | 利用无血清培养基从成纤维细胞中获得神经细胞的方法 | |
CN101294146B (zh) | 诱导神经干细胞分化的系统及诱导方法 | |
CN106244530A (zh) | 一种细胞培养液及其应用和诱导骨骼肌干细胞向心肌样细胞分化的方法 | |
CN113881624A (zh) | 一种细胞诱导的方法 | |
CN103060265A (zh) | 老年大鼠脑血管内皮细胞原代培养方法 | |
CN107164325B (zh) | MSCs来源的少突胶质细胞的制备方法及试剂盒 | |
CN109385399A (zh) | 一种羊水间充质干细胞分化为神经干细胞的方法 | |
CN105073978B (zh) | 利用植物干细胞或植物去分化干细胞的提取物诱导定制亚全能干细胞的方法以及利用该方法的方式制得的亚全能干细胞 | |
CN104130975B (zh) | 人源脂肪干细胞来源的神经元样细胞及其制备方法和应用 | |
CN103031274A (zh) | 小分子化合物tws119作为神经干细胞分化诱导剂的新应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240227 Address after: Room 104, Building 2, No. 198 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510700 Patentee after: Zhongke Meisi Stem Cell Regenerative Medical Technology (Guangzhou) Co.,Ltd. Country or region after: China Address before: 510530 open source Avenue 190, Science City, Luogang District, Guangzhou, Guangdong. Patentee before: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES Country or region before: China |